These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 3583222

  • 1. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy.
    Legler UF.
    Horm Metab Res; 1987 Apr; 19(4):168-70. PubMed ID: 3583222
    [Abstract] [Full Text] [Related]

  • 2. Impairment of prednisolone disposition in patients with Graves' disease taking methimazole.
    Legler UF.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):221-3. PubMed ID: 3335606
    [Abstract] [Full Text] [Related]

  • 3. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R.
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM, Shawkat W.
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese.
    Kamizono S, Hiromatsu Y, Seki N, Bednarczuk T, Matsumoto H, Kimura A, Itoh K.
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):759-64. PubMed ID: 10848881
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. E-rosette formation in Graves' ophthalmopathy.
    Sergott RC, Felberg NT, Savino PJ, Blizzard JJ, Schatz NJ.
    Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I.
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [Abstract] [Full Text] [Related]

  • 13. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy.
    Ozata M, Uckaya G, Bolu E, Corapcioglu D, Bingol N, Ozdemir IC.
    Med Sci Monit; 2001 Feb; 7(4):696-700. PubMed ID: 11433197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF, Scholz GH.
    Med Klin (Munich); 2004 Feb 15; 99(2):71-6. PubMed ID: 14963657
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
    Molnár I, Balázs C.
    Acta Med Hung; 1991 Feb 15; 48(1-2):13-21. PubMed ID: 1813853
    [Abstract] [Full Text] [Related]

  • 18. Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves' disease.
    Izumi M, Larsen PR.
    J Clin Invest; 1977 Jun 15; 59(6):1105-12. PubMed ID: 577211
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L.
    Clin Endocrinol (Oxf); 1997 Jul 15; 47(1):9-14. PubMed ID: 9302365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.